Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A4047 Gen1047 (Anti-B7-H4 & CD3) Gen1047 is a bispecific monoclonal antibody targeting CD3 on T cells and B7-H4. It induces T-cell-mediated cytotoxicity against B7-H4-positive cancer cells, making it a potential immunotherapy for malignant solid tumors with immunostimulating and antineoplastic activities. M.W 144.48 kDa.
A4050 Imm0306 (Anti-CD20 & CD47) IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa
A4002 Cadonilimab (Anti-PD-1 & CTLA-4) Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.
A4003 Pm8002 (Anti-PD-L1 & VEGF) Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.
A4004 Lutikizumab (Anti-IL-1α & IL-1β) Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.
A4006 Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.
A4007 Duligotuzumab (Anti-EGFR & HER3) Duligotuzumab is a dual-action humanized IgG1 antibody that blocks ligand binding to the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). By inhibiting these interactions, it disrupts signalling from all ligand-dependent HER dimers and induces antibody-dependent cell-mediated cytotoxicity. It exhibits enhanced efficacy in EGFR inhibitor-resistant SCCHN and NSCLC models, with potential benefits for tumors with high neuregulin 1 (NRG1) expression. MW: 144.78 KD.
A4008 Epcoritamab (Anti-CD20 & CD3) Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 KD.
A4009 Rilvegostomig (Anti-PD-1 & TIGIT) Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.
A4010 Elranatamab-Bcmm (Anti-BCMA & CD3) Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.
A4011 Hb0025 (Anti-PD-L1 & VEGF) Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
A4012 Tqb2858 (Anti-PD-L1 & TGF-β) Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.
A4013 Istiratumab (Anti-HER3 & IGF-1R) Istiratumab is a fully human tetravalent bispecific antibody that binds to and co-inhibits IGF-1R and the epidermal growth factor family of receptor tyrosine kinases B3 (ErbB3), with potential anti-tumor activity. MW: 199.64 KD.
A4014 Hx009 (Anti-CD47 & PD-1) Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.
A4015 Glofitamab (Anti-CD20 & CD3) Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.
A4016 TNB-383B (Anti-BCMA & BCMA & CD3) TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD.
A4017 Mas825 (Anti-IL-18 & IL-1β) Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: 144.15 kDa.
A4018 Romilkimab (Anti-IL-13 & IL-4) Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.
A4019 Linvoseltamab (Anti-BCMA & CD3) Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.
A4020 Abt-122 (Anti-IL-17 & TNF-alpha) Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.